The global burden of CLL increased from 40,537 cases in 1990 to 103,467 in 2019.
Continued approval required further verification and description of clinical benefit in confirmatory trials.
Survival outcomes were similar with the PET-driven approach and standard care.
Despite an inferior rate of seroconversion, lymphoma patients treated with anti-CD20 therapy did mount T-cell responses.
The overall response rate was 86.2%, and the complete response rate was 69.1%.
Researchers sought to determine the risk of comorbidities in younger patients who survive NHL compared with older patients.
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
The guideline focuses on the treatment of CRS and ICANS in patients undergoing CAR-T therapy for hematologic cancers.
At a median follow-up of 15.9 months, the median duration of response was not reached.
The “myTcell” app is expected to be released in the United States in 2022.
There was 1 case of grade 3 CRS and 1 case of grade 4 CRS.
Data were analyzed from patients diagnosed with CLL between 2000 and 2020 from 77 institutions affiliated with the ERIC.
The findings support the use of acalabrutinib in patients with relapsed/refractory CLL, including those with high-risk features.
Investigators revealed unequal access to novel agents when comparing Black and White patients with CLL.
The retrospective study included 559 patients who had received ibrutinib for CLL, of whom 179 progressed according to iwCLL criteria.
Researchers presented updated findings from the GLOW trial.
The FDA has issued a temporary policy for when it may not be feasible to have 2 doses of tocilizumab on-site.
Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.
The median event-free survival was 3 months in both treatment arms.
Vaccine responses were evaluated after dose 1 for 158 CLL patients, after dose 2 for 506 patients, and after dose 3 for 66 patients.